Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy

The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogetofte Barnkob, Mike, Vitting-Seerup, Kristoffer, Rønn Olsen, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327123/
https://www.ncbi.nlm.nih.gov/pubmed/35919495
http://dx.doi.org/10.1093/immadv/ltac009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327123/
https://www.ncbi.nlm.nih.gov/pubmed/35919495
http://dx.doi.org/10.1093/immadv/ltac009

Ejemplares similares